Add to ORKGA Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumor
PURPOSE: Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost im...
BACKGROUND: Futibatinib is an oral, irreversible, highly selective fibroblast growth factor receptor...
[[abstract]]Background: S-1 is a new oral fluoropyrimidine-derived combo and has been shown activity...
Background A phase I study to assess the maximum tolerated dose (MTD) of a short course of afatinib ...
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subject...
IF 3.502International audienceBackground Afatinib, an irreversible ErbB family blocker, has shown sy...
Background: In this phase Ib, dose-escalation study, the oral irreversible ErbB family blocker afati...
Background In this phase Ib, dose-escalation study, the oral irreversible ErbB family blocker afatin...
Item does not contain fulltextLESSONS LEARNED: Afatinib and selumetinib can be combined in continuou...
Background: Fruquintinib (Fruq) is a potent, highly selective, novel vascular endothelial growth fac...
PURPOSE: To determine the maximum tolerated dose (MTD) of volasertib, a Polo-like kinase inhibitor, ...
The safety, pharmacokinetics and efficacy of sorafenib plus docetaxel in patients with advanced refr...
Lessons LearnedAfatinib and selumetinib can be combined in continuous and intermittent dosing schedu...
Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-l...
Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II do...
PURPOSE: Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost im...
BACKGROUND: Futibatinib is an oral, irreversible, highly selective fibroblast growth factor receptor...
[[abstract]]Background: S-1 is a new oral fluoropyrimidine-derived combo and has been shown activity...
Background A phase I study to assess the maximum tolerated dose (MTD) of a short course of afatinib ...
A phase 1, open-label, dose-escalation study of BIIB022 (anti-IGF-1R monoclonal antibody) in subject...
IF 3.502International audienceBackground Afatinib, an irreversible ErbB family blocker, has shown sy...
Background: In this phase Ib, dose-escalation study, the oral irreversible ErbB family blocker afati...
Background In this phase Ib, dose-escalation study, the oral irreversible ErbB family blocker afatin...
Item does not contain fulltextLESSONS LEARNED: Afatinib and selumetinib can be combined in continuou...
Background: Fruquintinib (Fruq) is a potent, highly selective, novel vascular endothelial growth fac...
PURPOSE: To determine the maximum tolerated dose (MTD) of volasertib, a Polo-like kinase inhibitor, ...
The safety, pharmacokinetics and efficacy of sorafenib plus docetaxel in patients with advanced refr...
Lessons LearnedAfatinib and selumetinib can be combined in continuous and intermittent dosing schedu...
Inhibition of farnesyltransferase (FT) activity has been associated with in vitro and in vivo anti-l...
Purpose: Objectives of this dose-finding study were to determine the MTD and recommended phase II do...
PURPOSE: Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost im...
BACKGROUND: Futibatinib is an oral, irreversible, highly selective fibroblast growth factor receptor...
[[abstract]]Background: S-1 is a new oral fluoropyrimidine-derived combo and has been shown activity...